France’s healthcare system is currently navigating disruptions in the supply of several essential hospital medications, according to recent reports from the National Agency for the Safety of Medicines and Health Products (ANSM). The issues, identified between December 19, 2025, and January 6, 2026, span treatments for various conditions-including cancer and bleeding disorders-and underscore ongoing vulnerabilities within pharmaceutical supply chains that have impacted patients throughout 2024, with nearly 39% reporting medication shortages[[3]].This report details the latest developments, including temporary solutions involving imported medications and revised resupply schedules.
Une spécialité colombienne en dépannage.peterspiro / iStock / Getty Images Plus / via Getty Images
Several hospital-distributed medications are experiencing supply disruptions in France, according to recent reports from the National Agency for the Safety of Medicines and Health Products (ANSM). These issues, identified between December 19, 2025, and January 6, 2026, impact treatments for a range of conditions and highlight the fragility of pharmaceutical supply chains.
Fluorouracil Pfizer Availability Update
Table of Contents
Fluorouracil Pfizer 50 mg/mL solution for infusion (fluorouracil) is among the medications affected.
ANSM Availability Status
Lenalidomide Mylan: Resupply Schedule
Various strengths of Lenalidomide Mylan – 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, and 25 mg capsules (lenalidomide) are experiencing varying degrees of availability.
ANSM Availability Status
Resupply is expected by the end of February 2026 for the 5 mg, 10 mg, and 20 mg dosages.
- The 15 mg dosage has been available since mid-November 2025.
- The 25 mg dosage has been available since the end of November 2025.
- The 2.5 mg and 7.5 mg dosages have been available since the end of December 2025.
Paclitaxel AHCL: Resupply Delayed
Paclitaxel AHCL 6 mg/mL solution for infusion (paclitaxel) is facing a delay in its resupply.
ANSM Availability Status
Wilfactin: Supply Issues and Temporary Solution
Wilfactin 100 UI/mL powder for solution for injection (human von Willebrand factor) is experiencing ongoing supply challenges. The situation at hospitals remains tense, as previously reported on July 8, 2025.
ANSM Availability Status
- The ANSM reports a persistent tension in hospital supply of Wilfactin.
- A temporary and exceptional supply of Wilfactin 1000 UI/10 mL, lyophilized powder for injection, originally intended for the Colombian market, is being utilized.
- Wilfactin is currently reserved for patients requiring long-term prophylactic treatment.
Additional Information from the Manufacturer
A letter from the LFB laboratory to healthcare professionals (dated October 14, 2025) confirms that the batch manufactured by LFB meets the manufacturing, release, and control standards outlined in the marketing authorization (AMM) registered in France for WILFACTIN 100 UI/mL.
It is important to note that this imported batch:
- is labeled with an “Export” article code and description on your delivery slip.
- is not serialized.
- and each packaged unit only has two traceability labels (on the vial label). There is no traceability label on the packaging. Therefore, the packaging does not have the three traceability labels required by French regulations. It is requested that the information needed to ensure batch traceability be recorded manually or by any other appropriate means.
